Cabaletta Bio posted a GAAP net loss of USD 51.02 million, improving from USD 45.13 million a year earlier.
GAAP loss per share narrowed to USD 0.34 from USD 0.73 in the prior-year quarter.
R&D expenses climbed to USD 44.43 million from USD 37.64 million, while G&A costs eased to USD 7.59 million from USD 8.27 million.
Cash, cash equivalents and short-term investments rose to USD 225.1 million at June 30, 2026; funding runway guided into mid-2027.
Registrational RESET-Myositis data remains slated for mid-2027, supporting a planned 2H27 BLA filing for rese-cel; RESET-SSc ILD registrational enrollment targeted for 4Q26.
CABA•
